This Market Spotlight report covers the Cachexia market, comprising epidemiology, key marketed and pipeline drugs, clinical trials, and probability of success.
Key Takeaways
Key Takeaways
- Oxandrin, an orally active formulation of the anabolic steroid oxandrolone, is the only marketed drug available for cachexia. The greatest proportion of industry-sponsored drugs in active clinical development for cachexia are in Phase I, with only one drug in Phase III.
- Therapies in active clinical development for cachexia focus on targets such as ghrelin receptor and GDNF receptor alpha-like (GFRAL). These drugs are administered via the oral and subcutaneous routes.
- The overall likelihood of approval of a Phase I metabolic-other asset is 8.6%, and the average probability a drug advances from Phase III is 70.6%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 9.1 years in the overall metabolic space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for cachexia have been in the early and midphases of development, with 65% of trials in Phase I–II, and only 35% in Phase III–IV.
- The US has a substantial lead in the number of cachexia clinical trials globally, while the UK leads the major European markets. Clinical trial activity in the cachexia space is dominated by completed trials. Helsinn and Bristol Myers Squibb have the highest number of completed clinical trials for cachexia, with six trials each.
- Helsinn leads industry sponsors with the highest overall number of clinical trials for cachexia, followed by Bristol Myers Squibb and GlaxoSmithKline.
Table of Contents
OVERVIEWKEY TAKEAWAYSMARKETED DRUGSPIPELINE DRUGSPROBABILITY OF SUCCESSAPPENDIX
DISEASE BACKGROUND
TREATMENT
EPIDEMIOLOGY
CLINICAL TRIAL LANDSCAPE
BIBLIOGRAPHY
LIST OF FIGURES
LIST OF TABLES
